N Jewel Samadder1,2,3, Ken Robert Smith1,4, Jathine Wong1, Alun Thomas5, Heidi Hanson1,6, Kenneth Boucher1, Cathryn Kopituch1, Lisa A Cannon-Albright5,7, Randall W Burt1,2,8, Karen Curtin1,5. 1. Cancer Control and Population Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City 2. Huntsman Cancer Institute, Department of Medicine (Gastroenterology), University of Utah, Salt Lake City 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona 4. Huntsman Cancer Institute, Department of Family and Consumer Studies, University of Utah, Salt Lake City 5. Huntsman Cancer Institute, Department of Medicine (Genetic Epidemiology), University of Utah, Salt Lake City 6. Huntsman Cancer Institute, Department of Family Medicine and Prevention, University of Utah, Salt Lake City 7. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah 8. Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City
Abstract
Importance: The data describing cancer risks associated with Lynch syndrome are variable. Objectives: To quantify the prevalence of families that fulfill the Amsterdam I or II criteria for Lynch syndrome in the Utah population and investigate the risk of colonic and extracolonic cancers in family members and their relatives. Design, Setting, and Participants: In a population-based study, 202 families with Amsterdam I and II criteria–positive pedigrees in the Utah Population Database were identified. Of these, all cancer diagnoses in members of families with Amsterdam criteria and their first-degree, second-degree, and first-cousin relatives were located through linkage to the Utah Cancer Registry. The study was conducted from May 1 to June 30, 2016. Main Outcomes and Measures: Standardized morbidity ratios (SMRs) were estimated by comparing the observed rates of cancer in relatives with population-expected rates estimated internally from the Utah Population Database. Results: A total of 202 families meeting Amsterdam criteria for Lynch syndrome accounted for 2.6% of all colorectal cancers in the state; of these, 59 met both the Amsterdam I and Amsterdam II criteria. Cancers observed in significant excess in the first-degree relatives of Amsterdam criteria pedigrees included colorectal (SMR, 10.10; 95% CI, 9.43-10.81), endometrial (SMR, 5.89; 95% CI, 5.09-6.78), stomach (SMR, 2.90; 95% CI, 2.02-4.03), small intestine (SMR, 7.72; 95% CI, 5.17-11.08), prostate (SMR, 1.94; 95% CI, 1.73-2.17), kidney (SMR, 3.22; 95% CI, 2.45-4.16), urinary bladder (SMR, 1.62; 95% CI, 1.22-2.12), thyroid (SMR, 2.26; 95% CI, 1.55-3.17), and non-Hodgkin lymphoma (SMR, 2.10; 95% CI, 1.64-2.65). Risks of colorectal and endometrial cancers were also found to be elevated in second-degree (SMR, 4.31; 95% CI, 3.98-4.65 and SMR, 2.70; 95% CI, 2.30-3.14, respectively) and first-cousin (SMR, 1.85; 95% CI, 1.70-2.00 and SMR, 1.50; 95% CI, 1.29-1.73, respectively) relatives of families with Amsterdam criteria. Conclusions and Relevance: In this population-based study of cancer risk in families fulfilling the Amsterdam criteria, many of the cancers previously reported to be associated with Lynch syndrome were observed, several previously unreported cancer associations were noted, and the risk of colorectal and endometrial cancer were markedly increased in first-, second-, and even third-degree relatives of these families. This study provides clinicians with population-based, unbiased data to counsel members of families meeting the Amsterdam criteria regarding their elevated risks of cancer and the importance of cancer screening.
Importance: The data describing cancer risks associated with Lynch syndrome are variable. Objectives: To quantify the prevalence of families that fulfill the Amsterdam I or II criteria for Lynch syndrome in the Utah population and investigate the risk of colonic and extracolonic cancers in family members and their relatives. Design, Setting, and Participants: In a population-based study, 202 families with Amsterdam I and II criteria–positive pedigrees in the Utah Population Database were identified. Of these, all cancer diagnoses in members of families with Amsterdam criteria and their first-degree, second-degree, and first-cousin relatives were located through linkage to the Utah Cancer Registry. The study was conducted from May 1 to June 30, 2016. Main Outcomes and Measures: Standardized morbidity ratios (SMRs) were estimated by comparing the observed rates of cancer in relatives with population-expected rates estimated internally from the Utah Population Database. Results: A total of 202 families meeting Amsterdam criteria for Lynch syndrome accounted for 2.6% of all colorectal cancers in the state; of these, 59 met both the Amsterdam I and Amsterdam II criteria. Cancers observed in significant excess in the first-degree relatives of Amsterdam criteria pedigrees included colorectal (SMR, 10.10; 95% CI, 9.43-10.81), endometrial (SMR, 5.89; 95% CI, 5.09-6.78), stomach (SMR, 2.90; 95% CI, 2.02-4.03), small intestine (SMR, 7.72; 95% CI, 5.17-11.08), prostate (SMR, 1.94; 95% CI, 1.73-2.17), kidney (SMR, 3.22; 95% CI, 2.45-4.16), urinary bladder (SMR, 1.62; 95% CI, 1.22-2.12), thyroid (SMR, 2.26; 95% CI, 1.55-3.17), and non-Hodgkin lymphoma (SMR, 2.10; 95% CI, 1.64-2.65). Risks of colorectal and endometrial cancers were also found to be elevated in second-degree (SMR, 4.31; 95% CI, 3.98-4.65 and SMR, 2.70; 95% CI, 2.30-3.14, respectively) and first-cousin (SMR, 1.85; 95% CI, 1.70-2.00 and SMR, 1.50; 95% CI, 1.29-1.73, respectively) relatives of families with Amsterdam criteria. Conclusions and Relevance: In this population-based study of cancer risk in families fulfilling the Amsterdam criteria, many of the cancers previously reported to be associated with Lynch syndrome were observed, several previously unreported cancer associations were noted, and the risk of colorectal and endometrial cancer were markedly increased in first-, second-, and even third-degree relatives of these families. This study provides clinicians with population-based, unbiased data to counsel members of families meeting the Amsterdam criteria regarding their elevated risks of cancer and the importance of cancer screening.
Authors: Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt Journal: Am J Gastroenterol Date: 2015-02-03 Impact factor: 10.864
Authors: Matthew B Yurgelun; Matthew H Kulke; Charles S Fuchs; Brian A Allen; Hajime Uno; Jason L Hornick; Chinedu I Ukaegbu; Lauren K Brais; Philip G McNamara; Robert J Mayer; Deborah Schrag; Jeffrey A Meyerhardt; Kimmie Ng; John Kidd; Nanda Singh; Anne-Renee Hartman; Richard J Wenstrup; Sapna Syngal Journal: J Clin Oncol Date: 2017-01-30 Impact factor: 44.544
Authors: John Scott Maul; Ned R Warner; Scott K Kuwada; Randall W Burt; Lisa A Cannon-Albright Journal: Am J Gastroenterol Date: 2006-07 Impact factor: 10.864
Authors: Douglas K Rex; David A Johnson; Joseph C Anderson; Phillip S Schoenfeld; Carol A Burke; John M Inadomi Journal: Am J Gastroenterol Date: 2009-02-24 Impact factor: 10.864
Authors: H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan Journal: Gastroenterology Date: 1996-04 Impact factor: 22.682
Authors: Jonathan W Wischhusen; Chinedu Ukaegbu; Tara G Dhingra; Hajime Uno; Fay Kastrinos; Sapna Syngal; Matthew B Yurgelun Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-15 Impact factor: 4.254
Authors: Sowmya Jonnagadla; Sharelle L Joseland; Sibel Saya; Nicole den Elzen; Joanne Isbister; Ingrid M Winship; Daniel D Buchanan Journal: Hered Cancer Clin Pract Date: 2022-07-15 Impact factor: 2.164
Authors: Pandu P Nugroho; Siti Alyaa S Ghozali; Daniel D Buchanan; Mia I Pisano; Jeanette C Reece Journal: J Cancer Res Clin Oncol Date: 2022-10-17 Impact factor: 4.322
Authors: Jennifer L Beebe-Dimmer; Ashley L Kapron; Alison M Fraser; Ken R Smith; Kathleen A Cooney Journal: J Clin Oncol Date: 2020-03-24 Impact factor: 44.544